Abstract
SummaryThe lymphocytes of patients with ovarian carcinoma have been shown to be sensitized to antigenic determinants on ovarian tumour cells or in tumour cell membrane extracts. The blastogenic assay was used to demonstrate that normal female controls, as well as patients with ovarian cancer and pregnant women, also show in vitro responses to ovarian tumour extracts. There is a significant difference between parous and nulliparous women (P < 0·007) in their ability to respond. The lower incidence of parous women with ovarian cancer may result from previous sensitization to onco-fetal antigens during pregnancy
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call